Phase II Study of Apatinib Combined With Oral Vinorelbine in Pretreated Metastatic HER2 Negative Breast Cancer

NCT02768415 Phase 2 UNKNOWN

The hypothesis of this study is to discover if the all-oral therapy with apatinib plus oral vinorelbine can shrink or slow the growth of pretreated HER2 negative metastatic breast cancer.

Details

Lead sponsor	Chinese Academy of Medical Sciences
Phase	Phase 2
Status	UNKNOWN
Enrolment	40
Start date	2016-06

Conditions

• Breast Cancer

Interventions

• Apatinib
• Oral Vinorelbine

Primary outcomes

• Progression free survival (PFS) among metastatic HER2 negative breast cancer treated with apatinib and oral vinorelbine — up to 1 year after the last patient enrolled

Countries

China